This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Anavex (AVXL) in Focus: Stock Moves 9.5% Higher
by Zacks Equity Research
Anavex (AVXL) saw a big move last session, as its shares jumped nearly 10% on the day, amid huge volumes.
PPD Looks Good: Stock Adds 5.2% in Session
by Zacks Equity Research
PPD saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
Axonics (AXNX) Looks Good: Stock Adds 7.4% in Session
by Zacks Equity Research
Axonics (AXNX) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
Personalis (PSNL) Looks Good: Stock Adds 8% in Session
by Zacks Equity Research
Personalis (PSNL) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.
Principia (PRNB) Looks Good: Stock Adds 9.4% in Session
by Zacks Equity Research
Principia (PRNB) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.
Adverum (ADVM) Surges: Stock Moves 6.2% Higher
by Zacks Equity Research
Adverum (ADVM) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
Here's Why Anavex Life Sciences (AVXL) is a Great Momentum Stock to Buy
by Zacks Equity Research
Does Anavex Life Sciences (AVXL) have what it takes to be a top stock pick for momentum investors? Let's find out.
Is Anavex Life Sciences (AVXL) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (AVXL) Outperforming Other Medical Stocks This Year?
Anavex Life Sciences (AVXL) Moves to Buy: Rationale Behind the Upgrade
by Zacks Equity Research
Anavex Life Sciences (AVXL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Has Anavex Life Sciences (AVXL) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (AVXL) Outperforming Other Medical Stocks This Year?
Anavex's Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Anavex Life Sciences.
Why You Shouldn't Bet Against Anavex Life Sciences (AVXL) Stock
by Zacks Equity Research
Anavex Life Sciences (AVXL) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Anavex Life Sciences (AVXL) Upgraded to Strong Buy: Here's Why
by Zacks Equity Research
Anavex Life Sciences (AVXL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Will Anavex Life Sciences Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor Anavex Life Sciences Corp.
Anavex Life Sciences (AVXL) Stock Moves -0.38%: What You Should Know
by Zacks Equity Research
In the latest trading session, Anavex Life Sciences (AVXL) closed at $2.62, marking a -0.38% move from the previous day.
Ultragenyx (RARE) Reports Wider-Than-Expected Loss in Q4
by Zacks Equity Research
Ultragenyx (RARE) reports a wider-than-expected loss and beats sales estimates in the fourth quarter of 2019.
Trevena (TRVN) Resubmits NDA for Pain Drug Oliceridine to FDA
by Zacks Equity Research
Trevena (TRVN) resubmits the NDA to the FDA for IV oliceridine for the management of moderate-to-severe acute pain.
Is Anavex Life Sciences (AVXL) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (AVXL) Outperforming Other Medical Stocks This Year?
Implied Volatility Surging for Anavex (AVXL) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Anavex (AVXL) stock based on the movements in the options market lately.
Arena's (ARNA) Heart Failure Candidate Gets Fast Track Status
by Zacks Equity Research
The FDA grants fast track status to Arena's (ARNA) early-stage candidate, APD418, for the treatment of decompensated heart failure.
Alexion to Start Pivotal Study on Ultomiris for ALS in Q1
by Zacks Equity Research
Alexion (ALXN) plans to initiate a phase III study on Ultomiris (ravulizumab) to treat amyotrophic lateral sclerosis.
Anavex Life Sciences (AVXL) Moves to Strong Buy: Rationale Behind the Upgrade
by Zacks Equity Research
Anavex Life Sciences (AVXL) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Amarin Posts '19 Preliminary Results, Gives 2020 Expense View
by Zacks Equity Research
Amarin's (AMRN) Vascepa sales witness strong growth. The trend is anticipated to continue in 2020. However, the operating expense guidance for 2020 was higher than expected, which probably pulled the stock down.
Will Anavex Life Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Anavex Life Sciences.
All You Need to Know About Anavex Life Sciences (AVXL) Rating Upgrade to Buy
by Zacks Equity Research
Anavex Life Sciences (AVXL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.